Related Experiment Video
Updated: Jul 4, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Incidental atherosclerotic renal artery stenosis diagnosed at cardiac catheterization: no difference in kidney
Nadia Zalunardo1, Caren Rose, Andrew Starovoytov
1Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. nadia.zalunardo@vch.ca
Insights
Renal artery stenting did not show significant benefit or harm for patients with atherosclerotic renal artery stenosis (ARAS). Further research is needed to determine the best management strategies for ARAS, impacting long-term kidney function.
Area of Science:
- Cardiology
- Nephrology
- Vascular Medicine
Background:
- Atherosclerotic renal artery stenosis (ARAS) is often incidentally diagnosed during cardiac catheterization.
- Long-term kidney function outcomes in ARAS patients are not well-established.
- Current practices increasingly assess renal arteries during cardiac investigations.
Purpose of the Study:
- To evaluate the long-term kidney function in patients with ARAS.
- To compare the efficacy of medical management versus stenting in ARAS patients.
- To identify predictors of kidney function decline in ARAS.
Main Methods:
- Retrospective analysis of a prospectively identified cohort undergoing coronary angiography.
- Patients with >=50% ARAS were managed medically, with stenting considered based on specialist recommendation.
- Longitudinal regression and Cox regression analyses were used to assess GFR changes and predictors of decline.
Main Results:
- Of 140 patients, 67 underwent stenting, primarily for kidney function preservation and resistant hypertension.
- No significant difference in the rate of GFR decline was observed between stented and unstented groups (-1.48 vs -1.49 ml/min/1.73 m(2)/year).
- Cerebrovascular disease was the only predictor of a >=25% GFR decline (HR 2.52).
Conclusions:
- Renal artery stenting for ARAS did not demonstrate a clear benefit or harm regarding kidney function.
- The significance and optimal management of ARAS remain uncertain.
- Further investigation is required to clarify the role of stenting in ARAS management.
Background:
The long-term kidney function of patients with atherosclerotic renal artery stenosis (ARAS) diagnosed incidentally at the time of cardiac catheterization is not well described despite the increasingly common practice of assessing these vessels at the time of cardiac investigation.
Methods:
This is a retrospective analysis of a cohort identified prospectively at the time of non-emergent coronary angiography. Those with >or=50% ARAS were managed medically and underwent stenting if recommended by their nephrologist and/or cardiologist. Longitudinal regression analysis was used to compare the annualized change in estimated glomerular filtration rate (GFR) in stented and unstented patients. Cox regression analysis was used to determine the predictors of a decline in GFR by >or=25%.
Results:
Of 140 patients, 67 (48%) were stented, mostly for preservation of kidney function (70.1%) and/or resistant hypertension (53.7%). Median follow-up time was 943 days. Stented patients were younger, had higher systolic blood pressure and more severe ARAS. The adjusted rate of change in GFR was -1.49 (95% CI -2.33 to -0.65) ml/min/1.73 m(2)/year in the unstented group, and -1.48 (95% CI -2.34 to -0.62) ml/min/1.73 m(2)/year in the stented group (p = 0.99). A decline of GFR >or=25% occurred in 42 (30%) patients; no patient required dialysis. Only the presence of cereberovascular disease was associated with this outcome (hazard ratio 2.52, 95% CI 1.56-5.41).
Conclusion:
We were unable to demonstrate a benefit or harm of renal artery stenting for ARAS, thus further increasing the uncertainty of the significance of these lesions and how they are best managed.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Imaging Studies VII: Vascular Imaging
Cardiac Catheterization I: Pre-Procedure Overview
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
